As Israel-based Teva Pharmaceuticals struggles to recuperate losses after one f its worst yearly performances, reports say the company may look to merge with counterparts within the US or Canada if it cannot find a new chief executive officer.
The generic drug maker may look to strike a deal with US-based Mylan Inc. or Canada-based Valeant Pharmaceuticals International. The company remains under threat, however, of a takeover by an activist investor, according to Matric Asset Advisors.
The company remains without a CEO as their last resigned last October; analysts are now awaiting the company’s next move.
A recently Supreme Court ruling places Teva in the line of fire for competition from rival generic drug makers producing Copaxone, a treatment for multiple sclerosis.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI